Decoding Finely-Tuned Gamma Oscillations in Chronic Deep Brain Stimulation for Parkinson's Disease

Authors: Marjolein Muller[a,b], Eline A.M.Y. Rouleau[b], Saskia van der Gaag[b], Rodi Zutt[b], Carel F. Hoffmann[c], Niels A. van der Gaag[c,d], Alfred C. Schouten[e], M. Fiorella Contarino[a,b*]

[a]   Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands

[b]   Department of Neurology, Haga Teaching Hospital, The Hague, the Netherlands

[c]   Department of Neurosurgery, Haga Teaching Hospital, The Hague, the Netherlands

[d]   Department of Neurosurgery, Leiden University Medical Centre, Leiden, the Netherlands

[e]   Department of Biomechanical Engineering, Delft University of Technology, Delft, the Netherlands

*   Corresponding author

Contact information corresponding author:
E-mail: fiorellacont@yahoo.it;
Postal address: dr. M.F. Contarino, Department of Neurology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.

Conflict of Interest: MFC is an independent consultant for research and educational issues of Medtronic (all fees to institution), is an independent consultant for research by INBRAIN (all fees to institution), provides research support/contracted research for Boston Scientific (all fees to institution) and received speaking fees for: ECMT (CME activity), and Boston Scientific (all fees to institution). All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding Sources: MM and MFC were supported by the European Union's Horizon Europe research and innovation programme under grant agreement number 101070865 (MINIGRAPH).

Abstract

Background: Finely-tuned gamma (FTG) activity, occurring as a narrowband oscillation between 60–100Hz or entrained to half the stimulation frequency, has been observed during ON periods and dyskinesia in Parkinson's disease (PD). However, the mechanisms and conditions causing FTG remain unclear. This study characterizes FTG in PD patients undergoing subthalamic nucleus (STN) deep brain stimulation (DBS), examining its prevalence and relationship with patient characteristics and stimulation parameters.

Methods: Local field potentials (LFP) recorded across PD patients implanted with Sensight^{TM} leads and a Percept^{TM} PC neurostimulator were retrospectively analyzed for the occurrence of FTG. A comprehensive list of clinically relevant questions was composed to guide the analysis.

Results: Across LFP from 67 PD patients (134 STN) in various clinical states, naturally occurring (naive) and entrained FTG were observed in 11% and 33% of STN, respectively. Entrainment was more frequent during 180Hz than 125/130Hz simulation, but occasionally showed an artifactual origin. In line with the Arnold Tongue framework 1:2 entrainment ceased at high stimulation amplitudes, and showed an inverse relation to 1:1 entrainment. In specific cases, activity at the stimulation frequency was seen in the non-stimulated contralateral hemisphere.

Conclusions: This study provides novel insights into the dynamics and prevalence of both naive and entrained FTG in PD patients with STN-DBS across various clinical states. The study confirms the possibility of 1:1 entrainment but also shows the selective occurrence, potential artifactual origin, and cross-hemisphere influences of entrainment. Future research should investigate the mechanistic pathways underlying FTG, and its value in adaptive DBS.

Keywords

Deep Brain Stimulation; Local Field Potentials; Parkinson's Disease; Finely-tuned Gamma; Neural Entrainment

1. Introduction

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has become an established therapy for motor symptoms in Parkinson's disease (PD), especially for individuals refractory to pharmacological treatments [1, 2]. Although PD patients benefit significantly from DBS, the programming and optimization process can be burdensome, and its subjectivity can introduce variability in patient outcomes [3]. Novel neurostimulation devices allow the recording of local field potential (LFP) directly from the chronically implanted DBS electrodes [4]. LFP represent the integrated activity of synaptic potentials and provide insight into the functioning of basal ganglia circuits [5, 6]. Recent advances in the use of LFP recordings from the implanted leads present the possibility to refine the initial programming and the ongoing adjustments of DBS, offering a more objective and data-driven approach [7-9]. As potential neural biomarkers, LFP could guide more precise and individualized DBS therapy adjustments [10, 11].

Research on LFP has traditionally focused on the beta frequency band (13-35Hz), which correlates with bradykinesia and rigidity in PD [12, 13]. Beta oscillations are modulated by treatments such as levodopa and STN-DBS, representing a potential physiomarker for DBS programming [10, 11]. However, establishing fully automated and reliable DBS protocols based merely on beta frequency activity remains challenging [14-16]. Consequently, recent interest has turned toward the prokinetic gamma frequency band. Specifically, finely-tuned gamma (FTG) activity defined as narrowband (i.e. ≤10Hz) activity within the range of 60 to 100Hz, has been shown to correlate with (medication- or stimulation-induced) ON state and dyskinesia in PD patients [17-21].

The use of FTG presents a possible avenue for improving DBS programming and adaptive stimulation protocols, alone or in combination with beta power [17, 22, 23]. FTG can be detected both as spontaneous activity (naive FTG) and as an entrained response to stimulation (entrained FTG) [21, 24]. This entrainment typically is detected at half the stimulation frequency (1:2 entrainment), creating predictable patterns associated with ON periods during DBS therapy [17, 25, 26]. Nevertheless, the mechanisms behind, and the conditions (i.e. medication state, stimulation parameters, and presence of specific symptoms such as dyskinesias) under which FTG emerges and becomes entrained by stimulation, remain poorly understood due to limited and contradicting research on this specific topic [17, 23, 24, 26]. Additionally, the Arnold Tongue framework, which is based on the theory of coupled

oscillators, has been proposed by recent studies to describe the relation between the occurrence of entrainment and the applied stimulation parameters, has not been fully validated. An important element of the framework includes the transition of 1:2 entrainment to other frequencies, such as the stimulation frequency (1:1 entrainment): the occurrence of such transitions has not yet been established in clinical recordings [25, 26]. Furthermore, since entrained FTG is a subharmonic of the stimulation frequency, it is occasionally still hypothesized that the observed entrainment may reflect a stimulation artifact instead of a physiological response [16, 27]. It currently remains unclear if, and when, this may be the case.

This study aims to further clarify the characteristics of FTG in PD patients with STN-DBS, with a particular focus on its prevalence and relationship with patient characteristics and stimulation parameters as observed in daily practice. Furthermore, we explore the relationship between 1:2 and 1:1 entrainment as well as the relation with established effects of stimulation in the beta frequency band. By reporting these daily practice observations, we wish to strengthen and challenge some of the currently accepted concepts about the clinical associations and origin of FTG in PD, and to provide inspiration for future studies into this topic.

2. Materials and Methods

2.1 Study design

The Medical Ethical Committee Leiden-Den Haag-Delft waived review for the data collection (reference N23.007). All patients were asked if they objected to the use of their data in research through the standard opt-out procedure.

The primary aim of this study was to investigate the characteristics and occurrence of FTG in LFP recordings. To address this, a comprehensive list of clinically relevant questions was composed to guide the analysis and focus on key aspects of FTG. The proposed questions were answered when possible based on the available data.

1. What are the characteristics of naive FTG / entrained FTG?
    a. At what frequency band(s) does naive FTG / entrained FTG occur?
    b. What is the bandwidth of this naive FTG / entrained FTG activity?
    c. Is the power of naive FTG / entrained FTG (with the same stimulation amplitude) stable or does it fluctuate over time?
    d. If it fluctuates, how long does naive FTG / entrained FTG last in a single recording?
    e. Is entrained FTG modulated by different stimulation amplitudes or stimulation frequencies?
    f. If present, is naive FTG / entrained FTG always visible in all contact pairs in one hemisphere or is it location-specific?
    g. Is there an influence of unilateral stimulation in the non-stimulated hemisphere?
2. Does entrained FTG represent activity of the same neurons responsible for the naive FTG and/or beta-activity?
    a. Is entrained FTG only observed in recordings and channels where the naive FTG was also present? If entrained FTG follows naive FTG, does the entrained FTG start at the frequency of naive FTG?
    b. Is naive FTG / entrained FTG in ON medication state only observed in recordings and channels where there was a beta in OFF medication state? If naive FTG / entrained FTG follows beta, does the naive FTG / entrained FTG start at the same time when the beta stops?

      c. Is the strongest OFF beta recorded in the same contact pairs as the strongest naive or entrained FTG? Is there a relationship in the variation in amplitude between beta and naive or entrained FTG?

3. What is the clinical association of naive FTG / entrained FTG with patient state characteristics?

      a. Does naive FTG / entrained FTG only occur in association with dyskinesia?

      b. In which clinical state does naive FTG / entrained FTG occur? (ON/OFF-medication, ON/OFF-stimulation, or during a stun effect (i.e. temporary improvement of motor symptoms due to a surgically created microlesion) (<1 month post-op))

      c. If naive FTG / entrained FTG also occurs in the OFF state (OFF-medication / no stun effect, >3 months post-op), is this associated to the presence of tremor?

2.2 Patients

PD patients bilaterally implanted in the STN with directional leads (Sensight™ B33005, 1-3-3-1 design with 0.5mm spacing between contacts) and who received a sensing-enabled neurostimulator (Percept™ PC, Medtronic, Minneapolis) as a first implant or replacement between January 1st, 2020, and June 1st, 2023 were screened for inclusion. All patients with at least one BrainSense™ recording, were included and all the recordings made in that period in the context of clinical care were collected and used for the analysis.

2.3 Local field potential and clinical data collection

Contact-level bipolar LFP recordings for the (virtual) rings of the Sensight™ lead were obtained using the Percept™ PC neurostimulator. These recordings were conducted according to the standard of care with the patient seated in either the OFF or ON medication state, depending on the clinical requirements. Recordings were performed at different times after surgery, including during the standardized monopolar review approximately 10-days post-operatively, as well as during other routine follow-up visits starting from the first day to several years after surgery.

BrainSense™ recordings were visualized using custom Matlab scripts (version R2022b, MathWorks®). The visualized recordings were screened to identify the presence or absence of FTG or broadband gamma. The presence of FTG was defined as visible narrowband (i.e. ≤10Hz) activity between 40 and 100Hz, the presence of broadband gamma was defined as

visible broadband (i.e. >10Hz) between 40 and 100Hz. Both could be distinguished from background activity by the naked eye. A distinction was made between "Naive FTG", defined as FTG at a frequency unrelated to the stimulation frequency, and "Entrained FTG" activity positioned at precisely half the stimulation frequency (1:2 entrainment) or at the stimulation frequency (1:1 entrainment).

If FTG was present, several characteristics were documented, including stimulation settings (frequency, amplitude, pulse width, active contact-level), occurrence channel, FTG frequency and amplitude and any fluctuations thereof. Clinical characteristics of the patient during all included recordings were gathered from the electronic patient files, including medication state; presence of symptoms (tremor, rigidity, bradykinesia, and dyskinesia); and time after lead implantation.

2.4 Local field potential pre-processing and analysis

Time-domain data from the BrainSense^{TM} Survey, Setup, Indefinite Streaming, and Streaming recordings were converted to the frequency domain for visualization using power spectral density plots and spectrograms through the methods applied in the existing "PerceptToolbox" in Matlab [16]. BrainSense^{TM} Events, which are only stored in the frequency domain, were also visualized using a modified version of the existing scripts.

For BrainSense^{TM} Streaming recordings, a z-score for the beta (15-30Hz), naive FTG, 1:2 entrained FTG, and, if possible, stimulation frequency activity/1:1 entrainment (120-125Hz) were determined and visualized. For normalization, activity in the beta frequency band was compared to the activity in the 5-45Hz band; activity at the naive and entrained FTG frequencies was compared to the full gamma-band (40-100Hz); and, in the case of stimulation at 125Hz, the activity at the stimulation frequency was compared to the activity between 110 and 120Hz.

3. Results

3.1 Study population

In 67 patients (136 STNs) at least 1 recording was performed within the study period. In 31 of these patients (49 STN, 36%), FTG was identified in at least one recording. Entrained FTG occurred in 28 patients (16 bilateral and 12 unilateral), whereas naive FTG was visible in 9 patients (6 bilateral and 3 unilateral), of which 6 patients (4 bilateral, 2 unilateral) also showed entrained FTG. **Figure 1** provides a summary of the amount of STN showing different forms of gamma activity in varying stimulation and recording conditions. The clinical characteristics of patients with and without FTG are shown in **Table 1**.

3.2 Characteristics of naive and entrained FTG

3.2.1 Naive FTG

Naive FTG occurred at frequencies within 63Hz to 96Hz . The bandwidth of this activity ranged between 5Hz and 9Hz. The intensity and frequency-location of the naive FTG signal varied over time within a single recording (**Figure 2**) as well as between recording sessions. If naive FTG was present in the stimulation OFF-state, it lasted throughout the entire recording, although, the occurrence and power varied between contact pairs (**Figure 2**).

3.2.2 Entrained FTG

1:2 entrainment
Within the studied recordings, 1:2 entrainment with a bandwidth of approximately 5Hz was observed in 44 STN. In three additional patients (5 STN) stimulated at 180Hz (5/20, 25%), 1:2 entrainment persisted with stimulation at 0mA (**Figure 3B**). The persistence of subharmonic patterns after stimulation cessation suggests an artifactual origin in these specific cases which can be explained by the hardware switching of the stimulation even at 0mA, which is not present in the stimulation OFF state [28]. In all patients stimulated with 125/130Hz 1:2 entrainment did not persist at 0mA.

STN stimulated at 180Hz exhibited 1:2 entrainment more frequently (in 11/20, 55%) than STN stimulated at 125Hz (33/118, 28%) or 130Hz (1/4, 25%). The median stimulation amplitude required for 1:2 entrainment was lower with stimulation at 180Hz (1.3mA, IQR: 0.8mA) compared to 125/130Hz stimulation (2.6mA, IQR: 1.1mA). Additionally, in one patient, 1:2 entrainment only occurred in a single hemisphere during 125Hz stimulation and in both hemispheres with 180Hz stimulation.

In three patients (4 STN), stimulation at 125Hz resulted in 1:2 entrainment, as well as activity at 1:4 and 3:4 of the stimulation frequency (**Figure 3A**).

1:1 entrainment

In general, activity around the stimulation frequency of 125Hz is considered a stimulation artifact. In case of a stimulation artifact the power around 125Hz correlated with the changes in the stimulation amplitude (**Figure 3**). However, 11 STN (25%) in our population showed a variation in power around 125Hz which did not correlate with changes in the stimulation amplitude, we consider this a 1:1 entrainment effect (**Figure 4**). In these cases, an increase in 1:2 entrainment power often corresponded with a decrease in 1:1 entrainment power, and vice versa, implicating an inverse relation. In 1 out of 11 STN, no 1:2 entrainment occurred within the same recording. In cases without variation in power around 125Hz, the presence of 1:1 entrainment could not be excluded due to the potentially larger influence of a stimulation artifact. The presence of 1:1 entrainment for 180Hz stimulation could not be evaluated here because of the sampling rate of 250hz inherent to the Percept™ PC system.

The intensity of the entrained FTG power fluctuates over time within a single recording, as well as between recording sessions, partially independent of stimulation amplitude (**Figure 4 and 5**). BrainSense™ Streaming recordings with stimulation ramping from 0mA to 4mA and back to 0mA were available for 20 STN with 1:2 entrainment. In 8 of these STN recordings (40%), the 1:2 entrainment diminished before stimulation was reduced (**Figure 5**). Across 6 of these STN, cessation of 1:2 entrainment led to 1:1 entrainment (in 9 /12 recording channels). The median stimulation amplitude at which 1:2 entrainment disappeared or transitioned was 3.0mA (IQR: 0.6mA). This disappearance occurred after a median duration of 35 seconds (IQR: 7.5 seconds).

In most cases, 1:2 entrainment was observed across all contact pairs within a single STN in the same session. However, in 5 out of 44 STN (11%), 1:2 entrainment only occurred in some of the contact pairs. In 10 patients (13 STN), for which recordings from both hemispheres were available during 125Hz stimulation ramping from 0mA to 4mA, unilateral stimulation led to bilateral activity at the stimulation frequency (**Figures 3 and 4**).

3.3 Interconnectivity between entrained FTG, naive FTG and beta

3.3.1 Relation between entrained FTG and naive FTG

Naive FTG was detected in 10 STN exhibiting also 1:2 entrained FTG. Entrained FTG during stimulation was not always associated with the presence of naive FTG in the stimulation OFF

stimulation state, even within the same session. In 34/44 STN with entrained FTG, no naive FTG was recorded. Additionally, in 5/15 STN with naive FTG, no entrainment occurred. Nevertheless, in specific recordings, a relation between entrained and naive FTG was observed, showing a transition between naive and entrained FTG (**Figures 6 and 7**). In the 10 STN where naive FTG preceded 1:2 entrainment, the involved contact pairs overlapped.

In 11/44 STN (25%) with 1:2 entrainment, a broadband gamma activity accompanied the narrow 1:2 entrainment. This broad activity spanned a bandwidth of 15-40Hz, often showing a downward transition from 100Hz to 40Hz within a recording session during stimulation ramp-up (**Figure 5**). This broadband gamma activity only occurred in select cases during monopolar review with stimulation ramping, thus relation to movements performed by the patient cannot be excluded.

3.3.2 Relation between FTG and beta

In those contact pairs where naive or entrained FTG occurred in the ON medication state, beta-activity was present in the OFF medication state. In 3 patients (4 STN) with naive FTG, distinct beta-activity was present alongside naive FTG activity in the same recordings ON medicaiton (**Figure 2A**). In all STN where stimulation ramping caused 1:2 entrainment, OFF-medication, beta-suppression due to the stimulation was evident (**Figure 7**). In 11 of these 18 STN (61%) beta-suppression preceded the onset of 1:2 entrainment, whereas in 7 STN (39%) beta-suppression occurred almost simultaneously with the appearance of 1:2 entrainment.

Based on the available data, no direct relationship was found between the contact pair with the maximum beta-activity in the OFF-state and the contact pair with the maximum FTG activity in the ON-state.

3.4 Associations between FTG, clinical state and dyskinesia

3.4.1 Naive FTG

All cases of naive FTG were either recorded ON-medication or during the stun effect period (<1 month post-operatively). Naive FTG occurred mostly in the OFF-stimulation state. However, in 3 out of 15 STN (20%) Naive FTG was present ON-stimulation, with a maximum stimulation amplitude of 1.8mA.

Although naive FTG was often associated with dyskinesia (7/9 patients, 88%), two patients were without dyskinesia during naive FTG recording. Additionally, not all 18 patients

experiencing dyskinesia displayed naive FTG (10/18 patients, 55% without naive FTG) (**Figure 2**).

3.4.2 Entrained FTG

Entrained FTG was mostly observed in the medication ON-state; however, 15 STN (34%) with entrained FTG were recorded in the OFF-medication state and in the absence of a stun effect (>3 months post-op). Among these, only one STN was from a patient whose primary symptom was tremor; in 8 STN, tremor was present but accompanied by bradykinesia and rigidity of similar severity, while in the remaining 7 STN, no tremor was observed. Among patients stimulated at 125Hz, 1:2 entrainment was not directly related to tremor as a primary symptom. Specifically, 29% of STN with tremor exhibited 1:2 entrainment at 125Hz, a proportion comparable to 1:2 entrainment across the overall population with stimulation at 125/130Hz. Patients stimulated at 180Hz all had tremor..

Entrained FTG did not show a clear relationship with dyskinesia; 14 patients (50%) with 1:2 entrainment did not experience dyskinesia at the time of the recordings. Of these patients six also showed 1:1 entrainment, representing 67% of the population with 1:1 entrainment. The required stimulation amplitude to produce 1:2 entrained FTG varied across patients and hemispheres. The median stimulation amplitude necessary for 1:2 entrainment onset was 1.5mA (IQR: 0.7mA).

4. Discussion

In this cohort we describe the characteristics and clinical correlations of naive FTG activity and of 1:2 stimulation-entrained FTG activity. In addition we postulate the existence and describe the characteristics of 1:1 stimulation-entrained FTG activity for stimulation at 125Hz. This activity showed an inverse relation with 1:2 entrainment in the stimulation ON-state and was sometimes seen also in the non-stimulated contralateral hemisphere.

We could not confirm the strict association of FTG activity with dyskinesia since both naive and entrained FTG were observed independently of dyskinesias and across varying clinical states. 1:2 entrainment was more frequent in patients receiving 180Hz compared to 125/130Hz stimulation. Of note, in specific cases, subharmonic activity of 180Hz stimulation was likely of artifactual origin, which warns caution in the interpretation of these findings.

Beta-activity showed an inverse relation with 1:2 entrainment when transitioning between states with and without stimulation.

4.1 Stimulation and medication effects

Consistent with prior research, we found that naive FTG predominantly appeared in the ON-medication state [29], although our findings also demonstrate that both naive and entrained FTG can emerge OFF-medication, supporting earlier findings that FTG may spontaneously align with effective DBS frequencies regardless of medication status [30, 31]. Notably, naive FTG occasionally emerged during low-amplitude stimulation, before entrained 1:2 activity, suggesting that naïve FTG may be rather correlated to a therapeutic threshold (ON state), independent of the effective treatment (i.e. stimulation or medication).

Previous studies have largely linked FTG to dyskinesias [18, 21, 32], with Duchet et al. (2023) even referring to "harmful entrainment" [33]. However, our findings support and expand evidence that both naive and entrained FTG can occur independently of dyskinesias [23, 26, 29, 31] highlighting the need to reassess FTG's clinical relevance beyond motor symptoms. No consistent link was found between patient or DBS characteristics and (entrained) FTG, except for its strong association with stimulation and medication states. Still, some patients did not show entrained FTG even under high stimulation or ON-medication, despite having dyskinesias, suggesting other contributing factors. Prior studies suggest STN lead location, individual surgical recovery (e.g., stun effect), and disease progression may play a role [34, 35]. Our data, however, did not support this, as FTG

presence was not clearly linked to stun effect or post-operative timing. These hypotheses merit further study.

We also show that higher-frequency stimulation (180 vs. 125Hz) led to more frequent 1:2 entrainment (55% vs. 28%), independent of tremor symptoms. This may reflect increased stimulation energy or naturally high STN neuron firing rates [36]. This is confirmed in clinical practice, where higher stimulation frequencies tend to lead to side-effects at lower stimulation amplitudes. However, high-frequency stimulation (e.g. ≥ 130Hz) are also hypothesized to reduce 1:2 entrainment, due to axonal or synaptic failure [25, 37]. Nonetheless, our data suggest that high stimulation frequencies require lower stimulation amplitude to achieve similar stimulation effects compared to lower frequency stimulation. This is consistent with the principles of the Arnold Tongue framework [25], which suggest that 180Hz stimulation requires lower stimulation amplitudes for the occurrence of 1:2 entrainment.

In some cases, subharmonic 90Hz activity during 180Hz stimulation was also present at 0mA and was not modulated by stimulation amplitude. In these instances, the subharmonic activity was likely artifactual. This may be due to the fact that the Percept^{TM} PC system is optimized for recording physiological signals free from stimulation artifacts within a frequency range up to 80Hz [28]. Since 90Hz falls outside the optimized recording range, the system may have limitations in recording at this frequency, making it more susceptible to stimulation artifacts.

Our findings reveal that naive FTG and entrained FTG are inherently unstable, fluctuating independently of medication or stimulation settings. In several cases, 1:2 entrainment ended before stimulation amplitude was lowered or during ramping up of the stimulation, suggesting desynchronization at half the stimulation frequency may result from increased amplitudes or synaptic fatigue from high-frequency stimulation [25, 37].

4.2 Inter-frequency connectivity

In most cases 1:2 entrainment cessation led to increased activity at the stimulation frequency, consistent with 1:1 entrainment. Notably, stronger 1:2 entrainment was often linked to reduced power at the stimulation frequency, which returned as 1:2 power declined, suggesting a competitive interaction between these rhythms, possibly due to shared neural pathways. This aligns with 1:1 entrainment modeled by Sermon et al. (2023) [25], and supported by cellular imaging studies showing strong membrane depolarizations at stimulation and

harmonic frequencies in rodents, free from stimulation artifacts [38]. These observations confirm the physiological basis of entrained FTG and support previous findings that DBS-induced entrainment depends on a fine balance between stimulation parameters and neuronal dynamics [29, 31]. The inconsistent relationship between 1:2 and 1:1 entrainment may reflect variable contributions from stimulation artifacts for activity at 125Hz.

In 10 patients (13 STNs) with bilateral recordings during 125Hz stimulation ramping from 0–4mA in one hemisphere, activity at the stimulation frequency was detected in the non-stimulated STN, mirroring changes in the stimulated side. This suggests interhemispheric influence, as shown previously [39, 40]. However, no other effects, like beta-suppression, were observed in the non-stimulated STN. It remains unclear whether this cross-hemispheric activity caused symptom relief. Still, when assessing 1:1 entrainment, contralateral stimulation effects must be considered to avoid mistaking artifacts for true physiological responses.

In several cases with 1:2 entrainment, broadband gamma activity also occurred, with a bandwidth of 15–40Hz, shifting from higher (~100Hz) to lower (~40Hz) frequencies within single sessions. Similar broadband activity has been linked to contralateral movements [41, 42], suggesting that in our recordings this activity might be caused by patients performing motor tasks (e.g., finger tapping) during monopolar reviews [26]. Alternatively, this may reflect a transition between naive and entrained FTG, as proposed by Mathiopoulou et al. (2025) [26], though this does not explain persistent activity during 1:2 entrainment or at frequencies below the 1:2 entrainment frequency. Our data also showed a consistent inverse correlation between beta-activity and FTG, particularly entrained FTG, supporting an antagonistic relationship [24, 31]. Interestingly, naive FTG co-occurred with beta peaks in 3 patients (4 STNs), though beta-suppression may still have occurred. Future work should explore the mechanisms linking beta and FTG.

The dynamic interplay between beta and FTG suggests entrained FTG could be a useful biomarker for adaptive DBS, complementing beta-activity for more tailored therapy. Unlike beta or naive FTG, entrained FTG's spatial specificity make it particularly promising for real-time modulation. A combined beta–FTG approach may improve adaptive DBS algorithms, offering more precise symptom control across diverse patients [17, 21, 23, 26, 31]. However, as not all patients exhibit entrained FTG, personalized strategies remain essential.

4.3 Limitations and future directions

This study has several limitations, including its retrospective design and lack of a standardized protocol, leading to variability in data collection and limiting generalizability. Irregular recording times and diverse patient states further hindered the identification of consistent FTG features. High-amplitude stimulation (>4mA) and could not be systematically assessed due to clinical constraints. Furthermore, the impact of other stimulation parameters and duration on entrainment remains unclear.

Future research should employ structured, prospective protocols to assess FTG stability and characteristics over time and across clinical contexts. Studies should also examine the influence of post-operative factors (e.g., stun effect), disease progression, and stimulation parameters on FTG and entrainment. Crucially, understanding the interactions between beta-activity, naive FTG, 1:2, and 1:1 entrainment in both conventional and adaptive DBS could advance the use of combined biomarkers. This may enable more effective, personalized DBS therapies for patients with Parkinson's disease and related disorders.

4.4 Conclusions

This study provides novel insights into the prevalence, dynamics, and clinical significance of both naive and entrained FTG in patients with PD undergoing STN-DBS. Contrary to traditional views, our findings demonstrate that FTG—both naive and entrained—can occur independently of dyskinesias and during varying clinical states.

Importantly, we confirm the possibility of recording 1:1 entrainment and its interaction with 1:2 entrainment in line with the Arnold Tongue framework. We emphasize the inherent instability of naive and entrained FTG, its complex interactions with other oscillatory activities such as beta rhythms, and its potential as a complementary biomarker for adaptive DBS. However, the observed selective occurrence of entrained FTG in some patients, the possibility of an artifactual origin and the cross-hemisphere influences reinforce the need for a cautious and tailored approach in DBS therapy.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments

The authors are thankful to Prof. Dr. J.J. van Hilten and Dr. E. Lowet for their helpful insights.

Authors' Roles

- Marjolein Muller: design, execution, writing, and editing of the final version of the manuscript
- Saskia van der Gaag: execution, and editing of the final version of the manuscript
- Rodi Zutt: execution, and editing of the final version of the manuscript
- Eline Rouleau: editing of the final version of the manuscript
- Carel Hoffmann: editing of the final version of the manuscript
- Niels van der Gaag: editing of the final version of the manuscript
- Alfred Schouten: design, and editing of the final version of the manuscript
- Fiorella Contarino: design, execution, writing, and editing of the final version of the manuscript

Financial Disclosures of all authors

MFC is an independent consultant for research and educational issues of Medtronic (all fees to institution), is an independent consultant for research by INBRAIN (all fees to institution), provides research support/contracted research for Boston Scientific (all fees to institution) and received speaking fees for: ECMT (CME activity), and Boston Scientific (all fees to institution). All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1]   Ince NF, Gupte A, Wichmann T, Ashe J, Henry T, Bebler M, et al. Selection of optimal programming contacts based on local field potential recordings from subthalamic nucleus in patients with Parkinson's disease. Neurosurgery. 2010;67(2):390-7.

[2]   Pintér D, Járdaházi E, Balás I, Harmat M, Makó T, Juhász A, et al. Antiparkinsonian Drug Reduction After Directional Versus Omnidirectional Bilateral Subthalamic Deep Brain Stimulation. Neuromodulation. 2023;26(2):374-81.

[3]   Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. Mov Disord. 2006;21 Suppl 14:S284-9.

[4]   Medtronic. PERCEPT PC-NEUROSTIMULATOR medtronic.eu20202020 [Available from: https://europe.medtronic.com/xd-en/healthcare-professionals/products/neurological/deep-brain-stimulation-systems/percept-pc.html.

[5]   Lashgari R, Li X, Chen Y, Kremkow J, Bereshpolova Y, Swadlow HA, et al. Response properties of local field potentials and neighboring single neurons in awake primary visual cortex. J Neurosci. 2012;32(33):11396-413.

[6]   Einevoll GT, Kayser C, Logothetis NK, Panzeri S. Modelling and analysis of local field potentials for studying the function of cortical circuits. Nat Rev Neurosci. 2013;14(11):770-85.

[7]   van Wijk BCM, de Bie RMA, Beudel M. A systematic review of local field potential physiomarkers in Parkinson's disease: from clinical correlations to adaptive deep brain stimulation algorithms. J Neurol. 2023;270(2):1162-77.

[8]   Binder T, Lange F, Pozzi N, Musacchio T, Daniels C, Odorfer T, et al. Feasibility of local field potential-guided programming for deep brain stimulation in Parkinson's disease: A comparison with clinical and neuro-imaging guided approaches in a randomized, controlled pilot trial. Brain Stimulation. 2023;16(5):1243-51.

[9]   Radcliffe EM, Baumgartner AJ, Kern DS, Al Borno M, Ojemann S, Kramer DR, et al. Oscillatory beta dynamics inform biomarker-driven treatment optimization for Parkinson's disease. J Neurophysiol. 2023;129(6):1492-504.

[10]   Caffi L, Romito LM, Palmisano C, Aloia V, Arlotti M, Rossi L, et al. Adaptive vs. Conventional Deep Brain Stimulation: One-Year Subthalamic Recordings and Clinical Monitoring in a Patient with Parkinson's Disease. Bioengineering [Internet]. 2024; 11(10).

[11]   Arlotti M, Palmisano C, Minafra B, Todisco M, Pacchetti C, Canessa A, et al. Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient. Movement Disorders. 2019;34(5):757-9.

[12]   Kühn AA, Tsui A, Aziz T, Ray N, Brücke C, Kupsch A, et al. Pathological synchronisation in the subthalamic nucleus of patients with Parkinson's disease relates to both bradykinesia and rigidity. Exp Neurol. 2009;215(2):380-7.

[13]   Brown P. Abnormal oscillatory synchronisation in the motor system leads to impaired movement. Curr Opin Neurobiol. 2007;17(6):656-64.

[14]   Xu SS, Lee WL, Perera T, Sinclair NC, Bulluss KJ, McDermott HJ, et al. Can brain signals and anatomy refine contact choice for deep brain stimulation in Parkinson's disease? J Neurol Neurosurg Psychiatry. 2022.

[15]   Nakajima A, Shimo Y, Fuse A, Tokugawa J, Hishii M, Iwamuro H, et al. Case Report: Chronic Adaptive Deep Brain Stimulation Personalizing Therapy Based on Parkinsonian State. Front Hum Neurosci. 2021;15:702961.

[16]   Thenaisie Y, Palmisano C, Canessa A, Keulen BJ, Capetian P, Jiménez MC, et al. Towards adaptive deep brain stimulation: clinical and technical notes on a novel commercial device for chronic brain sensing. J Neural Eng. 2021;18(4).

[17]   Oehrn CR, Cernera S, Hammer LH, Shcherbakova M, Yao J, Hahn A, et al. Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial. Nat Med. 2024;30(11):3345-56.

[18]   Güttler C, Altschüler J, Tanev K, Böckmann S, Haumesser JK, Nikulin VV, et al. Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism. Mov Disord. 2021;36(4):927-37.

[19]   Gilron Re, Little S, Perrone R, Wilt R, de Hemptinne C, Yaroshinsky MS, et al. Long-term wireless streaming of neural recordings for circuit discovery and adaptive stimulation in individuals with Parkinson's disease. Nature Biotechnology. 2021;39(9):1078-85.

[20]   Alegre M, López-Azcárate J, Alonso-Frech F, Rodríguez-Oroz MC, Valencia M, Guridi J, et al. Subthalamic activity during diphasic dyskinesias in Parkinson's disease. Mov Disord. 2012;27(9):1178-81.

[21]   Swann NC, de Hemptinne C, Miocinovic S, Qasim S, Wang SS, Ziman N, et al. Gamma Oscillations in the Hyperkinetic State Detected with Chronic Human Brain Recordings in Parkinson's Disease. J Neurosci. 2016;36(24):6445-58.

[22]   Muller M, van Leeuwen MFC, Hoffmann CF, van der Gaag NA, Zutt R, van der Gaag S, et al. From subthalamic local field potentials to the selection of chronic deep brain stimulation contacts in Parkinson's disease - A systematic review. medRxiv. 2024:2024.10.29.24316351.

[23]   Colombo A, Bernasconi E, Alva L, Sousa M, Debove I, Nowacki A, et al. Finely Tuned γ Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain-Sense Study. Mov Disord. 2025.

[24]   Wiest C, Tinkhauser G, Pogosyan A, He S, Baig F, Morgante F, et al. Subthalamic deep brain stimulation induces finely-tuned gamma oscillations in the absence of levodopa. Neurobiol Dis. 2021;152:105287.

[25]   Sermon JJ, Olaru M, Ansó J, Cernera S, Little S, Shcherbakova M, et al. Sub-harmonic entrainment of cortical gamma oscillations to deep brain stimulation in Parkinson's disease: Model based predictions and validation in three human subjects. Brain Stimul. 2023;16(5):1412-24.

[26]   Mathiopoulou V, Habets J, Feldmann LK, Busch JL, Roediger J, Behnke JK, et al. Gamma entrainment induced by deep brain stimulation as a biomarker for motor improvement with neuromodulation. Nat Commun. 2025;16(1):2956.

[27]   Sermon JJ, Benjaber M, Duchet B, Anso J, Olaru M, Starr PA, et al. 1:2 entrainment is not a device-induced artefact, except when it is. Brain Stimul. 2024;17(2):149-51.

[28]   Sanger ZT, Henry TR, Park MC, Darrow D, McGovern RA, Netoff TI. Neural signal data collection and analysis of Percept™ PC BrainSense recordings for thalamic stimulation in epilepsy. J Neural Eng. 2024;21(1).

[29]   Wiest C, Torrecillos F, Tinkhauser G, Pogosyan A, Morgante F, Pereira EA, et al. Finely-tuned gamma oscillations: Spectral characteristics and links to dyskinesia. Exp Neurol. 2022;351:12.

[30]   Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci. 2001;21(3):1033-8.

[31]   Muthuraman M, Bange M, Koirala N, Ciolac D, Pintea B, Glaser M, et al. Cross-frequency coupling between gamma oscillations and deep brain stimulation frequency in Parkinson's disease. Brain. 2020;143(11):3393-407.

[32]   Olaru M, Cernera S, Hahn A, Wozny TA, Anso J, de Hemptinne C, et al. Motor network gamma oscillations in chronic home recordings predict dyskinesia in Parkinson's disease. Brain. 2024;147(6):2038-52.

[33]   Duchet B, Sermon J, Weerasinghe G, Denison T, Bogacz R. How to entrain a selected neuronal rhythm but not others: open-loop dithered brain stimulation for selective entrainment. bioRxiv. 2022.

[34]   Trottenberg T, Fogelson N, Kühn AA, Kivi A, Kupsch A, Schneider GH, et al. Subthalamic gamma activity in patients with Parkinson's disease. Exp Neurol. 2006;200(1):56-65.

[35]   Jenkinson N, Kühn AA, Brown P. γ oscillations in the human basal ganglia. Exp Neurol. 2013;245:72-6.

[36]   Agnesi F, Muralidharan A, Baker KB, Vitek JL, Johnson MD. Fidelity of frequency and phase entrainment of circuit-level spike activity during DBS. J Neurophysiol. 2015;114(2):825-34.

[37]   Rosenbaum R, Zimnik A, Zheng F, Turner RS, Alzheimer C, Doiron B, et al. Axonal and synaptic failure suppress the transfer of firing rate oscillations, synchrony and information during high frequency deep brain stimulation. Neurobiol Dis. 2014;62:86-99.

[38]   Lowet E, Kondabolu K, Zhou S, Mount RA, Wang Y, Ravasio CR, et al. Deep brain stimulation creates informational lesion through membrane depolarization in mouse hippocampus. Nat Commun. 2022;13(1):7709.

[39]   Tabbal SD, Ushe M, Mink JW, Revilla FJ, Wernle AR, Hong M, et al. Unilateral subthalamic nucleus stimulation has a measurable ipsilateral effect on rigidity and bradykinesia in Parkinson disease. Exp Neurol. 2008;211(1):234-42.

[40]   Hasegawa H, Fischer P, Tan H, Pogosyan A, Samuel M, Brown P, et al. The Effect of Unilateral Subthalamic Nucleus Deep Brain Stimulation on Contralateral Subthalamic Nucleus Local Field Potentials. Neuromodulation. 2020;23(4):509-14.

[41]   Androulidakis AG, Kühn AA, Chen CC, Blomstedt P, Kempf F, Kupsch A, et al. Dopaminergic therapy promotes lateralized motor activity in the subthalamic area in Parkinson's disease. Brain. 2007;130(Pt 2):457-68.

[42]   Alegre M, Alonso-Frech F, Rodríguez-Oroz MC, Guridi J, Zamarbide I, Valencia M, et al. Movement-related changes in oscillatory activity in the human subthalamic nucleus: ipsilateral vs. contralateral movements. Eur J Neurosci. 2005;22(9):2315-24.

Figures

Figure 1. Flowchart providing an overview of the amount of STN showing different gamma activities across all the available BrainSense™ recordings. Recordings were available for 136 STN in total. Of these STN all had recordings OFF DBS, and most also ON DBS, either with 125/130Hz or 180Hz stimulation. For these three DBS states (OFF; ON-125/130Hz; ON-180Hz) the flowchart provides the amount of STN showing naive finely-tuned gamma (FTG) (i.e. narrowband activity between 40-100Hz at a semi-random frequency); 1:1 entrainment (i.e. activity at the stimulation frequency modulated independent from the stimulation amplitude); 1:2 entrainment (i.e. FTG activity entrained to ½ the stimulation frequency); 1:4 / 3:4 entrainment (i.e. FTG activity entrained to ¼ and/or ¾ the stimulation frequency); or a subharmonic artifact (i.e. activity at exactly ½ the stimulation frequency persisting unchanged with stimulation amplitude of 0mA). For some of the cases showing 1:2 entrainment, stimulation was ramped from 0mA to 4mA and back to 0mA. In some of these ramping cases one of the following was observed: cessation of 1:2 entrainment prior to a decrease in stimulation amplitude; presence of broadband gamma activity (i.e. broadband activity between 40-100Hz); or presence of bilateral activity at the stimulation frequency during unilateral DBS.

Figure 2. Power spectral density plots for local field potential recordings performed using BrainSense™ Survey in both hemispheres of three individuals during in-clinic visits. All recordings were performed in the ON-medication and OFF-stimulation states either with or without the patient experiencing dyskinesias. The spectrogram for the channel surrounding the clinically chosen stimulation contact is also shown. NL_034 **(A)** was recorded 1 day post-operatively while experiencing dyskinesia in both arms. The recording showed high beta and naive gamma activity in the left hemisphere, whereas the right hemisphere showed no beta activity (stun effect) and only limited naive gamma activity. NL_023 **(B)** was recorded 2 days post-operatively and showed no distinct beta activity in either hemisphere but strong naive gamma activity in the right hemisphere and limited naive gamma activity in the left hemisphere without experiencing dyskinesias. Finally, NL_043 **(C)** was recorded 101 days post-operatively. Interestingly, the recording showed low amounts of beta activity in the left hemisphere, and remarkably high amounts of beta activity in the right hemisphere, but no naive gamma activity whilst experiencing dyskinesias.

Figure 3. (A and B) Local field potential recordings performed during a single in-clinic visit (NL_059) 10 days after surgery in the OFF-medication state. **(A)** the LFP power across 5 to 120Hz during 125Hz stimulation in the channel 1-3 of the right hemisphere starting at 1mA and slowly ramped to 3.5mA and back to 2mA. In the right hemisphere a clear activity at half the stimulation frequency (1:2 entrainment) emerges when stimulation reaches 2.6mA. Next to this, activity at 1/4th and possibly 3/4th of the stimulation frequency is apparent. These subharmonics seemingly stop when stimulation is reduced to 2mA. In addition activity entrained at the stimulation frequency is present and seems modulated by the stimulation amplitude (stimulation artifact). Stimulation in the left hemisphere is consistently kept at 0mA, nonetheless activity around the stimulation frequency (125Hz) is present and modulated similarly to the contralateral side, suggesting relation with stimulation changes in the right hemisphere. **(B)** power across 5 to 120Hz during 180Hz stimulation in the right hemisphere for channel 0-2 at 0mA which is slowly ramped to 4mA before switching back to 0mA. Stimulation in the left hemisphere is consistently kept at 0mA. In both hemispheres a clear activity with mostly constant amplitude at half the stimulation frequency is visible throughout the entire recording independent from the stimulation amplitude and can be interpreted as subharmonic stimulation artifact. At certain timepoints vertical artifacts (activity throughout all frequencies due to impulse noise) are visible possibly causing the disruptions in the activity at half the stimulation frequency. **(C and D)** Activity at 1/2nd, 1/4th and 3/4th of the stimulation frequency was also captured in some of the at-home registered OFF events **(C)** and Dyskinesia events **(D)** in another patient (NL_036) stimulated at 125Hz between 2.5 and 3.5 months post-operatively.

Figure 4. Local field potential recordings were performed in patients NL_022 **(A)** and NL_070 **(B)** during an in-clinic visit using the BrainSense^{TM} Streaming function at 10 and 8 days post-operative, respectively, in the OFF-medication and ON-stimulation (125Hz) states. The patients did not experience dyskinesias during these recordings. The left column shows the spectrogram of the recording session whereas the right column shows the corresponding z-scores for frequencies 13-30Hz (beta), 60-65Hz (entrained FTG), and 120-125Hz (stimulation amplitude).

For patient NL_022 the stimulation at contact points 1 **(A1)** and 2 **(A2)** was ramped up from 0mA to 4mA and back to 0mA in the right hemisphere. No stimulation was applied in the left hemisphere at this time.

In patient NL_070 the stimulation at contact point 1 **(B1)** was ramped up from 0mA to 3mA and back to 0mA and in contact point 2 **(B2)** from 0mA to 4mA and back to 0mA in the left hemisphere. No stimulation was applied in the right hemisphere at this time. In all cases activity around the stimulation frequency occurred in the non-stimulated contralateral hemisphere.

For patient NL_022, stimulation through contact points 1 and 2 in the right hemisphere resulted in a decrease in the z-score for beta and an increase in the z-score for entrained FTG. The same was true for stimulation through contact point 2 in the left hemisphere of patient NL_070, however, during stimulation at contact point 1 no entrained FTG occurred. In all cases with entrainment, the z-score for entrained FTG lowered before decreasing the stimulation amplitude. However, for both patients only during stimulation through contact point 2 the increase of z-score for entrained FTG corresponds with a decrease in z-score for the activity at the stimulation frequency. The z-score for stimulation frequency activity recovers to its original course once the entrained FTG activity diminishes, independently of stimulation amplitude, suggesting 1:1 entrainment. The z-score for stimulation frequency activity in the non-stimulated contralateral hemisphere showed changes related to stimulation amplitude changes in the stimulated hemisphere.

Figure 5. Spectrogram for local field potential recordings performed in three individuals during in-clinic visits using the BrainSense™ Streaming function 10 days after surgery in the OFF-medication and ON-stimulation (125Hz) states. **(A1, B1)** show recordings performed across a single channel in a single hemisphere for two individuals (NL_054 and NL_057), in A1 no entrained FTG is visible, for B1 little entrained FTG is visible. **(A2, B2)** show recordings from the same patient at the same moment in time, but for a different hemisphere in NL_054 or a different channel in NL_057, here both recordings show entrained FTG across a narrow band between 60-65Hz, the narrow band shows intensity changes over time. Finally, **(C1, C2)** show recordings performed in a different patient (NL_022) for a short (left) and more extended stimulation period (right) in the same channel and hemisphere. Here in both cases entrained FTG occurs as a narrow band between 60-65Hz but gamma activity is also evident also throughout a broad range between 40-100Hz. The intensity of the entrained FTG diminishes before the stimulation amplitude is reduced.

Figure 6. Power spectral density plots for local field potential recordings performed using BrainSense™ Streaming in both hemispheres of a single patient (NL_006). Recordings were performed across three sequential sessions during a single in-clinic visit at 2 years and 4 months postoperatively, ON-medication whilst the patient was experiencing dyskinesias. In the first sessions the stimulation amplitude in the left hemisphere was decreased from 2.7mA to 0mA. During stimulation entrained finely-tuned gamma (FTG) was visible as a narrow band between 60-65Hz in both hemispheres. Once the stimulation was decreased in the left hemisphere the FTG frequency changed to 90Hz, suggesting a transition from entrained to naive FTG. In the second sessions the stimulation amplitude in the left hemisphere was increased from 0mA back to the original stimulation amplitude of 2.7mA. When stimulation was still set to 0mA naive FTG was visible around 90Hz in the left hemisphere, which changed to narrow band activity between 60-65Hz during stimulation (entrained FTG), suggesting a transition from naive to entrained FTG. Stimulation in the right hemisphere remained constant, leading to narrow band 60-65Hz entrained FTG throughout almost the entire session. At the end of the session stimulation was decreased instantly from 3.6mA to 0mA in the right hemisphere. The FTG activity between 60-65Hz disappeared at this moment. In the third and final session the stimulation amplitude in the right hemisphere was slowly ramped back to the original stimulation amplitude of 3.6mA. When stimulation was set to 0mA no FTG was visible. Once stimulation was ramped up entrained FTG appeared between 60-65Hz. In the left hemisphere stimulation amplitude and entrainment were constant throughout the session.

Figure 7. Power spectral density plots for local field potential recordings performed using BrainSenseTM Streaming in both hemispheres of a single patient (NL_045). Recordings were performed across two sequential sessions during a single in-clinic visit at 2 days postoperatively, ON-medication whilst the patient was experiencing dyskinesias. In the first session **(A)**, the stimulation amplitude for contact-level 1in the left hemisphere was ramped from 0mA to 4mA and back to 0mA. Before stimulation onset beta-activity was evident between 13 and 30 Hz. This beta-activity was slowly suppressed by stimulation, starting at 0.6mA, and showing complete suppression at 2.6mA. Naive finely-tuned gamma (FTG) activity occurred at a frequency-band of 104 to 110Hz during stimulation only, starting at 1.2mA, and lasting until 2.6mA stimulation. At this point naive FTG transitioned to 62.5Hz, representing 1:2 entrainment. When stimulation amplitude was decreased to 2.5mA 1:2 entrainment ceased, and naive FTG at the 104 to 110Hz band re-occurred, however, no transitional activity could be detected. Once stimulation amplitude was reduced to 0mA naive FTG ceased, and beta-activity re-occurred. No influences on activity in the non-stimulated, right hemisphere, were detected. A similar pattern was seen in the second session **(B)** for stimulation through contact-level 2 in the left hemisphere.

1 Tables

Table 1. Clinical characteristics of patients with and without naive and/or entrained finely-tuned gamma activity.

	Naive FTG (N = 9[3] patients) Median (range)	Entrained FTG (N = 28[3] patients) Median (range)	Bilateral no FTG (N = 36) Median (range)
Age at lead implant, years	63 (56-69)	66 (41-79)	61 (49-76)
Sex (male), N (%)	5 (55%)	21 (75%)	18 (50%)
Lead type, N (%):			
- 3389	0 (0%)	1 (3%)	5 (14%)
- Sensight™	9 (100%)	30 (97%)	31 (86%)
Percept PC, N (%):			
- Primary implant	9 (100%)	31 (100%)	33 (92%)
- Replacement	0 (0%)	0 (0%)	3 (8%)
Disease duration at lead implant, years	9 (5-20)	7 (2-20)	9 (3-21)
	Naive FTG (n = 15[4] STN)	Entrained FTG (n = 44[4] STN)	No FTG (n = 3+12+72 STN)[5]
Main Symptom[1], N (%):			
Tremor only	1 (7%)	4 (9%)	0+3+3 (7%)
Tremor combined[2]	5 (33%)	18 (41%)	0+2+18 (23%)
Bradykinesia/rigidity only	6 (40%)	18 (41%)	3+5+44 (60%)
Stun effect (no symptom)	3 (20%)	4 (9%)	0+2+7 (10%)
Time since implant at recording, days	86 (0-549)	56 (0-1220)	59 (0-1220)

[1] Main symptom per hemisphere based on MDS UPDRS-III scored in OFF-medication and OFF-stimulation state at 8-10 days post-operatively (during monopolar review).
[2] Tremor with similar MDS UPDRS-III score as bradykinesia and/or rigidity.
[3] Patients exhibiting both naive and entrained FTG were included in both subgroups (N = 6).
[4] STN exhibiting both naive and entrained FTG were included in both subgroups (n = 10).
[5] STN without FTG with respect to the patient group of origin (STN from the group of patients with naive + entrained + bilateral no FTG)
Abbreviations: FTG: finely-tuned gamma; N: number of patients; MPR: monopolar review; STN: subthalamic nucleus; n = number of STN.